One Shot, One Year: The Experimental Treatment That Slashed Cholesterol by 62%

You know that little pill bottle on your kitchen counter?

The one you're supposed to take every single day. The one your doctor keeps reminding you about. The one that, if you're being honest, you sometimes forget. Or skip because your muscles ache. Or just... don't refill.

You're not alone. In fact, you're in the majority.

Here's a staggering statistic: only about half of people take their cholesterol medication more than 80% of the time. And somewhere between 33% to 50% of patients quit their statins entirely within a year of starting them.

That's millions of people walking around with dangerously high cholesterol, not because the medications don't work, but because taking them every day is really, really hard.

But what if you didn't have to?

What if one treatment, a single infusion, one time, could slash your bad cholesterol for an entire year? Or longer?

That's exactly what a growing body of groundbreaking research is now showing. And it's not science fiction. It's happening right now, in clinical trials, with real patients.

Let's talk about what this means for you.

---

The Problem Nobody's Talking About

High cholesterol is sneaky. It doesn't hurt. It doesn't make you feel sick. There's no cough, no fever, no obvious sign that anything is wrong.

Instead, it quietly does its damage, building up plaque in your arteries, narrowing the pathways that carry blood to your heart and brain. And then, one day, without warning: a heart attack. A stroke.

Cardiovascular disease is the number one killer of adults in the United States and worldwide. And raised LDL cholesterol, the "bad" kind, is one of the biggest drivers.

The good news? We have effective treatments. Statins work. PCSK9 inhibitors work. Inclisiran works.

The bad news? They only work if you keep taking them.

And for all the reasons above, forgetfulness, side effects, cost, just plain being tired of pills, people don't.

Dr. Ann Marie Navar, a preventive cardiologist at UT Southwestern Medical Center, put it bluntly: "In spite of having a lot of available therapies, the majority of people do not have their LDL under control."

This isn't a failure of willpower. It's a failure of design. Daily medications ask something that human nature isn't great at delivering: perfect consistency, forever.

So researchers asked a different question:

What if we only had to do this once?

---

The Breakthrough That's Changing Everything

In November 2025, The New England Journal of Medicine, one of the most prestigious medical journals in the world, published results from a first-in-human clinical trial that made cardiologists sit up and take notice.

A single infusion of an experimental gene-editing treatment lowered heart-clogging cholesterol by about 50% over an entire year.

Not a pill a day. Not a shot every two weeks. One treatment. One year of results.

"If you'd asked me 15 years ago if we could have done something like this, I would have thought you were crazy," said Dr. Steven Nissen, the study's senior author and chief academic officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic.

The study was small, only 15 patients with dangerously high cholesterol that hadn't responded to other medications. But the results were overwhelmingly positive, especially in the four patients who received the highest dose.

"Is something like this truly a one and done? That was always the question," said lead study author Dr. Luke Laffin, a preventive cardiologist at Cleveland Clinic. "This new data is essentially saying that the decreases in LDL cholesterol and triglycerides we saw at 60 days after treatment have lasted over a year."

One year. And counting.

---

How Does It Actually Work?

Okay, let's get into the science. But I promise, I'll keep it simple.

Think of your DNA as a massive instruction manual for your body. Every cell in your body has a copy. And somewhere in that manual, there's a chapter called "How to Make Cholesterol."

Specifically, there's a gene called PCSK9 that plays a starring role in regulating LDL cholesterol. When PCSK9 is active, it makes it harder for your liver to clear "bad" cholesterol from your blood. When PCSK9 is less active, your liver can clear more cholesterol, and your levels drop.

The experimental treatments we're talking about work by turning down the volume on that PCSK9 gene, or on another related gene called ANGPTL3.

Think of it like this:

Imagine your liver is a sink, and cholesterol is water. Normally, the drain is partially blocked (that's PCSK9 doing its thing). These new treatments unclog the drain. And because they change the instructions rather than just temporarily fixing the symptom, the drain stays unclogged for a very long time.

Different approaches do this in different ways:

• CRISPR-Cas9 acts like "molecular scissors", it actually cuts the DNA at a specific spot to modify the gene.

• Base editing is more like a "find and replace" function, it changes a single letter in the genetic code without cutting the DNA.

• Epigenetic editing doesn't change the DNA sequence at all. Instead, it adds chemical "tags" that tell the gene to stay quiet, like putting a "do not disturb" sign on the door.

All three approaches are being tested. All three have shown impressive results. And all three share the same revolutionary promise: durable, long-lasting cholesterol reduction from a single treatment.

---

The Numbers That Made Scientists Cheer

Let's talk data, because the numbers here are genuinely exciting.

In the Cleveland Clinic's CRISPR trial targeting ANGPTL3:

• LDL cholesterol dropped by nearly 50% at the highest dose
• Triglycerides fell by almost 48%
• Effects were sustained for over a year with no safety concerns

Meanwhile, the VERVE-102 trial (targeting PCSK9 through base editing) reported even more dramatic results:

• LDL cholesterol fell by 51% to 88% depending on the dose
• At the highest dose, the average reduction was 62%, an absolute drop of 78 mg/dL
• Effects persisted for at least 18 months in the patients followed longest

"The treatment effect is as good as the best available therapies and, importantly, appears durable at least out to 18 months. This opens the door to a one-and-done future treatment paradigm," said Dr. Riyaz S. Patel, a study author and professor of cardiology at University College London.

And then there's the epigenetic approach: In non-human primate studies, a single dose achieved about 90% PCSK9 suppression and roughly 60% LDL reduction, with effects stable for 343 days and counting.

343 days. That's nearly a year from a single treatment.

---

Meet the Players: Three Approaches, One Goal

Let's break down the three main experimental approaches side by side:

1. CRISPR-Cas9 Targeting ANGPTL3 (Cleveland Clinic)

What it targets: The ANGPTL3 gene, a different cholesterol-regulating pathway than PCSK9

How it works: Molecular scissors cut the DNA to disable the gene

The data: ~50% LDL reduction, ~48% triglyceride reduction, sustained for 1+ year

Safety: No adverse effects reported in the highest-dose group

Fun fact: The idea came from studying people with a natural genetic mutation that gives them very low cholesterol for life.

2. VERVE-102 Base Editing Targeting PCSK9 (Eli Lilly)

What it targets: The PCSK9 gene

How it works: Base editing changes a single DNA letter to permanently turn down PCSK9 activity

The data: 51-88% LDL reduction depending on dose; 62% at highest dose; effects lasting 18+ months

Safety: Well tolerated across all doses; no serious adverse events; most common side effects were infusion reactions and fatigue

Status: Phase 1 complete; Phase 2 planned

3. Epigenetic Editing (Various Research Groups)

What it targets: PCSK9 gene expression

How it works: Adds chemical "tags" (methylation) to silence the gene without changing DNA sequence

The data: ~90% PCSK9 suppression, ~60% LDL reduction in primate studies

Safety: No serious liver toxicity; liver function returned to normal within 7 days

Key advantage: Potentially reversible, if something goes wrong, you might be able to "turn the gene back on"

---

How This Compares to What You're Taking Now

If you're currently managing high cholesterol, you're probably familiar with one or more of these:

Here's what's striking: The experimental one-time treatments are matching or exceeding the efficacy of the best available daily or weekly therapies.

Dr. Navar captured the potential perfectly: "If you're 20 and you have really high cholesterol, it may make a lot more sense to have a one-time treatment that doesn't require you to have to take a pill every single day or shot every two weeks for the next 60 years."

Think about that. 60 years of daily pills vs. one infusion.

For young people with familial hypercholesterolemia, a genetic condition that causes dangerously high cholesterol from childhood, this could be life-changing.

---

The Elephant in the Room, Is It Safe?

Let's address what you're probably thinking: "Gene editing sounds scary. What if something goes wrong?"

It's a fair question. And the researchers are asking it too.

Here's what we know so far:

In the Cleveland Clinic CRISPR trial: The four patients who received the highest dose showed no adverse effects over the full year of follow-up.

In the VERVE-102 trial: The treatment was "well tolerated across all dose levels, with no serious adverse events reported." The most common side effects were infusion-related reactions and fatigue.

In the epigenetic primate study: No severe liver injury was observed. Any liver function changes were temporary and resolved within 7 days.

But, and this is important, these are Phase 1 trials.

Phase 1 is primarily about safety, and the sample sizes are small (15 patients, 35 patients, etc.). We need larger trials (Phase 2 and Phase 3) to truly understand the safety profile, especially for rare side effects that might only show up in thousands of patients.

There's also the theoretical concern about off-target effects, the possibility that gene editing might accidentally modify the wrong gene. This is why researchers are developing more precise approaches like base editing and epigenetic editing, which carry lower theoretical risk.

The epigenetic approach has an additional safety feature: reversibility. If something goes wrong, researchers have shown they can use another tool to "turn the gene back on."

"More data on VERVE-102 has to be accrued for safety and efficacy," said Dr. Roger Blumenthal, a volunteer expert at the American Heart Association. "But the results so far are exciting, especially for people with really high LDL cholesterol levels."

---

What This Means for You (Right Now)

Okay, so here's the million-dollar question: Should you wait for this instead of taking your current medication?

No. Absolutely not.

Here's why:

1. These treatments are experimental. They're not approved by the FDA or any other regulatory body. It will likely be several years before they're available to the public, assuming larger trials go well.

2. High cholesterol is dangerous right now. Every day you're not managing it, plaque is building up in your arteries. Don't wait for a future solution when current solutions work.

3. The cost will be significant. Gene therapies are expensive. Similar treatments have been priced at over $1 million per dose. Even if prices come down, this won't be accessible to everyone immediately.

4. We don't know long-term outcomes yet. Will a one-time treatment really reduce heart attacks and strokes over decades? That will take years of follow-up to determine.

So what should you do?

Keep taking your current medications as prescribed. Talk to your doctor about any side effects, there may be alternatives that work better for you. And stay informed about these developments.

If you have familial hypercholesterolemia or very high risk, ask your cardiologist whether any clinical trials might be appropriate for you. But don't stop your current treatment.

---

This isn't just about cholesterol.

This is about a fundamental shift in how we think about treating chronic disease.

For decades, the model has been: take a pill every day, forever. And for many conditions, high blood pressure, diabetes, high cholesterol, that model has saved countless lives.

But it's also created a massive adherence problem. People forget. People get side effects. People get tired of being "patients." And when they stop taking their meds, they get sick.

What these experimental therapies represent is a move toward durable, one-time interventions, treatments that fix the underlying problem rather than just managing symptoms.

If this works for cholesterol, what else could it work for?

High blood pressure? Diabetes? Obesity?

We're at the very beginning of this revolution. And while there will be bumps along the way, safety questions, cost barriers, ethical considerations, the direction is clear.

Medicine is moving from management to correction.

From daily to one and done.

---

Let's come back to that pill bottle on your kitchen counter.

One day, maybe sooner than you think, it might not be there.

Instead of a daily reminder of your condition, you might have a single infusion that you barely remember. A treatment that works quietly in the background, keeping your arteries clear, protecting your heart, without asking anything of you day after day.

We're not there yet. But we're closer than we've ever been.

The experimental treatments we've talked about today, CRISPR targeting ANGPTL3, VERVE-102 base editing targeting PCSK9, epigenetic silencing, have all shown that a single treatment can slash bad cholesterol for a year or more, with no serious safety concerns in early trials.

"This is an extremely exciting milestone," said Dr. Patel.

It really is.

But for now, here's what matters most: Don't wait for the future to take care of your heart today.

Talk to your doctor. Take your medications. Make the lifestyle changes that support your health.

And keep watching this space, because the future of cholesterol treatment is arriving faster than anyone expected.

---

Frequently Asked Questions

Q: Can I get this treatment now? 

A: No. These treatments are experimental and not yet approved by regulators. They're only available through clinical trials.

Q: How long does the effect last? 

A: Current data shows effects lasting at least 12-18 months. Some researchers believe the effect could last a lifetime.

Q: Is gene editing safe? 

A: Early trials show no serious adverse effects. However, larger trials are needed to confirm safety.

Q: How much will it cost? 

A: Likely very expensive initially, similar gene therapies have cost over $1 million per treatment. Costs may decrease over time.

Q: Will this replace statins? 

A: Eventually, maybe. But for now, statins and other cholesterol medications remain the standard of care. Don't stop your current treatment.